Pharmacia and Upjohn

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Pharmacia and Upjohn sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed top decile by trial count

Pharmacia and Upjohn: 11 sponsored US clinical trials, none currently recruiting.

Pharmacia and Upjohn sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 2 trials.

Top-decile sponsor footprint

Pharmacia and Upjohn ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 2

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

NCT00002210

COMPLETED NA

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

NCT00002211

COMPLETED NA

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236

COMPLETED NA

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

NCT00002312

COMPLETED Phase 2

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322

COMPLETED NA

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002400

COMPLETED Phase 3

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123

COMPLETED NA

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094

COMPLETED NA

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002401

COMPLETED Phase 3

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

NCT00002124

COMPLETED Phase 1

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

NCT00002087

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 2

Therapeutic Areas

How the Pharmacia and Upjohn archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: HIV Infections (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Pharmacia and Upjohn: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Pharmacia and Upjohn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Pharmacia and UpjohnAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Pharmacia and Upjohn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pharmacia and Upjohn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Pharmacia and Upjohn page

11 registered trials is a research-attention snapshot, not an endorsement of Pharmacia and Upjohn or any single study.

  • None of Pharmacia and Upjohn's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • HIV Infections is the condition Pharmacia and Upjohn studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pharmacia and Upjohn pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.